A Clinical Study of Personalized Tumor Neoantigen Peptide Vaccine/neoantigen-based Dendritic Cells in the Treatment of Advanced Malignant Solid Tumors
Latest Information Update: 06 Mar 2025
At a glance
- Drugs HJ N 001 (Primary) ; Neoantigen-based-dendritic-cell-therapeutic-Shenzhen-Dengding-Biopharm (Primary)
- Indications Breast cancer; Cervical cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Pancreatic cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Sep 2023 Status changed from not yet recruiting to recruiting.
- 09 Mar 2023 New trial record